A Phase 2 interventional study of Infigratinib and Infigratinib in Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Enrolling by invitation at 31 sites in 10 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.
Among the 29 studies in Achondroplasia with a site in United States, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 19th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Tyra Biosciences, Inc · Sites in United States, Australia, Canada and 5 more countries
Ages 3–10
Ascendis Pharma A/S · Sites in United States, Australia, Austria and 12 more countries
Ages 0–2
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 6
First in 1996; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 325 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 76 across the 20 interventional studies, 271 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 9 most frequent:
This study is registered under QED Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, a BridgeBio company is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
BridgeBio has 5 studies filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Achondroplasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in participants with ACH who previously completed a QED-sponsored interventional study, and in additional participants who are naïve to infigratinib treatment. Quality of Life assessments for this participant population will also be evaluated. Treatment-naïve participants must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study if the sponsor deems additional long-term safety and/or efficacy data are necessary, and participants are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Key Rollover Participants Inclusion Criteria:
Key Rollover Participants Exclusion Criteria:
Key Inclusion Criteria for Treatment Naïve Participants:
Key Exclusion Criteria for Treatment Naïve Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children who have completed QED-sponsored interventional study with infigratinib (Phase 2 or Phase 3)
Drug: Infigratinib
Children naïve to infigratinib
Drug: Infigratinib
Infigratinib minitablets or sprinkle capsules to be administered by mouth. In participants that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day.
Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the participants naïve to Infigratinib will be 0.25 mg/kg/day.
Incidence of treatment emergent adverse events (TEAE) and serious TEAE
Time frame: 10 years
Changes over time in height Z-score in relation to ACH and general pediatric population tables
Time frame: 10 years
Changes over time in height velocity Z-score in relation to ACH and general pediatric population tables
Time frame: 10 years
Changes over time in body proportions
Time frame: 10 years
Changes over time in weight Z-score
Time frame: 10 years
Changes over time in BMI in relation to ACH and general pediatric population tables
Time frame: 10 years
Age of puberty onset and time to Tanner stage ≥4
Time frame: 10 years
Changes over time in number of episodes of otitis media per year
Time frame: 10 years
Changes over time in number of episodes and/or severity of sleep apnea
Time frame: 10 years
Changes over time in range of motion (elbow)
Time frame: 10 years
Changes over time in skeletal abnormalities of the lower extremities and spine
Time frame: 10 years
Changes in health-related Quality of life [HRQoL] as assessed by Pediatric Quality of Life Inventory (PedsQL)
Time frame: 10 years
Changes in health-related Quality of life [HRQoL] as assessed by Quality of Life in Short Stature Youth questionnaire (QoLISSY)
Time frame: 10 years
Overall pain as assessed by Numeric Rating Scale for pain (Pain-NRS)
Time frame: 10 years
Changes in functional abilities as evaluated by Functional Independence Measure for Children (WeeFIM)
Time frame: 10 years
Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Severity (PGI-S)
Time frame: 10 years
Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Change (PGI-C)
Time frame: 10 years
Participant and caregiver evaluation of treatment benefit as assessed by a qualitative interview
Time frame: 10 years
Changes in cognitive functions assessed by age-appropriate computerized tests
Time frame: 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2031, 119 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
QED Therapeutics, a BridgeBio company →